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Background: Programmes of pre-elimination of malaria have been implemented in Senegal since 2010, and the
burden of malaria has decreased substantially. These changes in the epidemiology should be monitored with
effective tools that allow changes in patterns of transmission to be estimated. In Dielmo and Ndiop, two villages of
Senegal with different malaria endemicity, infections have been followed longitudinally for 20 years, during which
time there have been several control interventions leading to substantial decreases of transmission. This study
aimed to compare malaria antibody responses of the inhabitants of these two villages, between 2000 and 2010,
using schizont crude extracts of a local strain of P. falciparum (Pf Sch07/03).
Methods: Sera collected from inhabitants of the two villages (141 from Dielmo and 79 from Ndiop in 2000; 143
from Dielmo and 79 from Ndiop in 2010) were used to assess the prevalence of antibodies against crude schizont
extracts of Pf Sch07/03. Three ages groups were defined: [5-9] yrs, [10-14] yrs and [15-19] yrs. Statistical comparisons
were performed. Seroprevalence and the magnitude of antibody responses were compared between age groups,
villages and periods.
Results: Overall seroprevalence to P.fSch07/03 decreased between 2000 and 2010 in both villages: from 94.4% to
44.4% in Dielmo and from 74.4% to 34.6% in Ndiop. The difference between Dielmo and Ndiop was highly
significant in 2000 (p < 0.001) but not in 2010 (p >0.20). The decrease in seroprevalence was larger in younger (more
than 40%) than older (less than 19%) inhabitants. Longitudinal monitoring of the younger group showed that
seroprevalence decreased between 2000 and 2010 in Dielmo from 98.7 to 79.3, but not in Ndiop from 67.6 to 66.7.
The magnitude of antibody responses in seropositive individuals was significantly higher in 2000 than 2010 for
both villages.
Conclusions: Crude extracts of P. falciparum are appropriate tools for evaluating malaria prevalence at different
periods, and in both low and high endemic area. Using crude extracts from local strains to assess transmission may
allow efficient evaluation of the consequences of control programs on malaria transmission.
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There has been significant progress over the last ten years
in the fight against malaria, a major threat to public
health. The World Health Organization (WHO) reported
that of 102 countries in which transmission continues, 52
recorded a decrease of more than 50% in the number of
malaria cases between 2000 and 2010. In parallel, malaria
mortality has also decreased by more than 45% globally
and, in particular, by 47% in Africa. These results have
been obtained by a combination of interventions, includ-
ing artemisinin-based combination therapy (ACT), exten-
sive coverage of exposed populations with long-lasting
insecticide-impregnated bed nets (LLITN), malaria diag-
nosis by rapid diagnostic tests (RDTs), and intermittent
treatment strategies [1]. The changes in malaria epidemi-
ology needs to be monitored through time by control
programmes to assess the effects of the strategies imple-
mented and to anticipate the consequences of changing
rates of malaria transmission [2]. Additional and appropri-
ate tools are required to evaluate transmission, because
parasite prevalence and entomological measures can be
insufficiently sensitive in areas of low transmission [3].
Various methods have been used since the 1960s to
measure humoral responses to malaria and thereby evalu-
ate malaria seroprevalence and transmission intensity.
However, the variability of sources of antigen and subjectiv-
ity of some of the detection methods led to these methods
falling out of favour [4]. Sensitive enzyme-linked immuno-
sorbent assay (ELISA) remains the most attractive tech-
nique for assessment of malaria transmission and changes
in prevalence following the establishment of control pro-
grammes [5]. Recent studies using characterized antigens
have concluded that the evaluation of antibody persistence
through cross-sectional surveys could be a complementary
or even an alternative approach to investigating markers of
malaria [6]. There are however constraints and limitations
to serological tests with characterized antigens: immuno-
logical responses to a given antigen may be, in part, genetic-
ally determined; and some of these antigens have the
potential to, or may, display substantial polymorphism [7].
Previous studies have shown that responses to crude ex-
tracts of malaria parasites, which are mixtures of numerous
antigens, are less sensitive to these constraints [5,8].
The objectives of this study were to assess the value and
feasibility of testing immune responses to parasite crude
extracts. This approach was used to evaluate changes in
malaria transmission over a ten year period in Dielmo and
Ndiop, two villages of Senegal where there has been
longitudinal follow-up since 1990. Various malaria inter-
ventions were implemented between 2000 and 2010, in
accordance with the recommendations of the National
Malaria Control Programme [9]. These interventions
were associated with a large decrease in malaria trans-
mission. The relationship between these changes andlocal populations antibody responses to crude parasite
extracts was investigated.
Methods
A cross-sectional study was conducted for the years
2000 and 2010 using the sera collected at the end of the
wet season, during the Dielmo and Ndiop cohort study
described previously [10,11].
Setting
At the beginning of the cohort studies, (in 1990 for Dielmo
and in 1993 for Ndiop), the features of malaria transmis-
sion risk differed between the two villages. At that time
Dielmo was an area where malaria was holoendemic with
substantial activity of the main mosquito vector Anopheles
gambiae sensu lato complex and, therefore, perennial para-
site transmission. By contrast, Ndiop was a mesoendemic
area with moderate and seasonal transmission: transmis-
sion was 10 times lower than that observed in Dielmo
[12,13]. The estimated annual entomological inoculation
rate (EIR) in these areas was established periodically during
the course of the cohort study. Between 2000 and 2010,
the EIR significantly changed in the two villages: 482 in-
fected bites/person/year in 2000 vs 88.7 infected bites/
person/year in 2010 for Dielmo and 79 infected bites/
person/year in 2000 vs 4.6 infected bites/person/year in
2010 for Ndiop.
The parasitaemia prevalence in November in the three
age groups defined in this study was respectively 48.1,
54.1 and 53.3% in 2000 versus 4.9, 8.1 and 8.7% in 2010
in Ndiop. This prevalence was 44.9, 25 and 25% in 2000
versus 0, 4.8 and 3.3% in 2010 in Dielmo.
Population
The study was conducted using sera collected from in-
dividuals less than 20 years of age. A total of 442 serum
samples from inhabitants of Dielmo and Ndiop col-
lected for the cohort study were included in this study:
220 for 2000 (141 from Dielmo and 79 from Ndiop) and
222 for 2010 (143 from Dielmo and 79 Ndiop). Socio-
demographic characteristics for the donors of these sera
were extracted from the database established for the
cohort study [10,11]. This study was examined and ap-
proved by the Senegalese National Health Research Eth-
ics Committee.
Plasmodium falciparum culture and crude extract
preparations
The P. falciparum strain 07/03 (Pf 07/03) was isolated
from a patient in Dielmo and adapted to culture in the
Immunology Unit of Pasteur Institute in Dakar [14]. Par-
asites were cultured continuously on O+ erythrocytes in
RPMI containing 0.5% Albumax in candle jars according
to the method described by Trager and Jensen [15].
Table 1 Demographic characteristics of the study
population
2000 2010 p.Value
N = 222 (%) N = 220 (%)
Location
Dielmo 144 (64.9) 141 (64.1) 0.9
Ndiop 78 (35.1) 79 (35.9)
Sex
Male 128 (57.7) 114 (51.8) 0.3
Female 94 (42.3) 106 (48.2)
Age
Mean 10.3 10.9 0.06
95% CI [9.9-10.8] [10.5-11.4]
Age groups
[5-9] yrs 109 (49.1) 87 (39.5) 0.07
[10-14] yrs 88 (39.6) 95 (43.2)
[15-19] yrs 25 (11.3) 38 (17.3)
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were prepared by the method published by Wahlgren
et al. [16]. After centrifugation of the culture, one vol-
ume of the pellet was lysed in three volumes of sterile
distilled water and vortexed for homogenization. The
extract was frozen without centrifugation at −80°C in
working aliquots.
ELISA assay
ELISA Maxisorp plates (Nunc, Roskilde, Denmark) were
used to optimize the dilution by dose effect. The optimal
dilution was 1/300 and this was used for coating. Plates
were coated with 100 μl of water-soluble crude extracts
of Pf07/03 schizonts (Sch07/03). Non-infected red blood
cell were diluted in PBS and distributed into some wells
on each plate as a control. The coated plates were incu-
bated overnight at 4°C and washed. Then, 200 μl of
blocking buffer (2% BSA in PBS with 0.05% Tween) was
added to each well and the plates incubated for 1 hour
at 37°C. Plasma samples were diluted at 1/200 in a dilu-
tion buffer (1% BSA in PBS with 0.05% Tween) and
100 μl of diluted serum was distributed into each well.
Negative and positive controls were included on each
plate: positive controls were from Dielmo/Ndiop hyper-
immune individuals and negative controls were from
European individuals. Polyclonal goat anti-human IgG
conjugated to peroxidase at a dilution of 1/6,000 in the
dilution buffer (1% BSA in PBS-Tween 0.05%) was then
added. Bound peroxidase was detected with ortho-
toluidine/H2O2 (100 μl) and the reaction was stopped by
addition of 4 N H2SO4 (50 μl/well). Between each incu-
bation phase, the ELISA plates were washed extensively
with PBS-0.05% Tween. The optical density (OD) at
450 nm was read in a BIO-RAD Microplate Reader
(iMark). The threshold for positivity was defined as an
OD ratio >2 (OD sample/OD naive serum). Inter-assay
variations for positive controls did not exceed 20%.
Statistical analysis
R software was used for statistical analysis [17]. Three age
groups were defined: [5-9] yrs, [10-14] yrs and [15-19] yrs.
The seroprevalence of anti-Sch07/03 antibodies (Abs) was
compared between 2000 and 2010 after standardization.
Fisher’s exact tests were used to compare categorical vari-
ables and antibody levels between the villages and between
the years 2000 and 2010. Non parametric tests (Kruskall
Wallis, Wilcoxon) and the Spearman test were used to
study non-parametric quantitative variables. Differences
were considered statistically significant for p < 0.05.
Results
Demographic characteristics
From the collection established for the cohort study in
Dielmo and Ndiop, 224 sera were randomly selected for2000 and 220 for 2010. Blood samples had been col-
lected during the rainy season in both years. Table 1
summarizes the characteristics of the study population.
The mean age was 10.3 years [9.9-10.8] in 2000 and
10.8 years [10.5-11.4] in 2010, with no significant differ-
ence between the groups for the two periods (p = 0.06).
There was also no difference in the sex ratio (57.7% male
in 2000 and 51.8% male in 2010).
Seroprevalence of Sch0703 antibodies was significantly
lower in 2010 than 2000
Standardized seroprevalence values were lower in 2000
than 2010, dropping from 94.4% to 44.4% in Dielmo and
74.4% to 34.6% in Ndiop (Figure 1). The difference in the
seroprevalence of Sch07/03 Abs in 2000 between Dielmo
and Ndiop was highly significant (p < 0.001), but this dif-
ference between Dielmo and Ndiop was much smaller,
and indeed not significant, in 2010 (p > 0.20).
Changes in seroprevalence of Sch07/03 antibodies,
according to age group
The prevalence of anti-Sch07/03 antibodies (Abs) was also
analysed in various age groups in each village (Figure 2).
For all age groups and for both villages, seroprevalence
was higher in 2000 than 2010. In 2000, the prevalence of
Sch07/03 Abs in Dielmo was high in every age group, and
was highest in the oldest group: 98.7% [5-9] yrs, 87.5%
[10-14] yrs and 100% [15-19] yrs. In Ndiop, the prevalence
of Sch07/03 Abs increased with age group: 67.6% [5-9]
yrs, 78.1% [10-14] yrs and 83.3% [15-19] yrs (Figure 2).
The prevalence of Sch07/03 Abs was lower in 2010 than
2000 both in Dielmo and Ndiop. In Dielmo the prevalence
values in 2010 were 34.6% in the [5-9] yrs age group,
Figure 1 Seroprevalence of Sch07/03 Abs in Dielmo and Ndiop after standardization.
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19] yrs age group. In Ndiop the 2010 values were 25.0% in
the [5-9] yrs age group, 31.6% in the [10-14] yrs age group
and 66.7% in the [15-19] yrs age group.
The 2010 seroprevalence values in the different age
groups in Dielmo were similar to those in Ndiop. The
seroprevalence had decreased more and more signifi-
cantly in the younger age group (by more than 40%)
than in the older age group (by less than 19%). To study
this decrease of seroprevalence, we compared the sero-
prevalence in the [5-9] yrs age group in 2000 and that
ten years later (2010) in the age group ten years olderFigure 2 Antibody responses to crude extracts of Sch07/03. Prevalenc
villages during 2000 and 2010.(the [15-19] yrs age group]. In Dielmo, the percentage of
positive samples was 98.7% in the [5-9] yrs age group in
2000 to 79.3% in [15-19] yrs age group in 2010. However
in Ndiop, the prevalence was unchanged: 67.6% in the
[5-9] yrs age group in 2000 and 66.7 in the [15-19] yrs
age group in 2010.
Changes in mean levels of antibodies to Sch07/03,
according to age group
A shift in the type of malaria transmission might be
reflected by the magnitude of the antibody response to
P. falciparum. To investigate this possible relation, thee percentages by age group after standardization in Dielmo and Ndiop
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mined in positive responders of the three age groups
(Figure 3). The magnitude of IgG responses was high in
children less than 10 years old, and increased with age
especially in Dielmo in 2000. For all age groups, in 2000,
the magnitude of the IgG response was greater in Dielmo
(mean OD ratios > 4) than Ndiop. In 2010, the mean levels
of antibodies against Sch07/03 were significantly lower
than in 2000 (mean OD ratios <3) and no significant dif-
ference in responses was found between age groups in the
two villages (Figure 3).
The mean levels of IgG antibodies for all subjects be-
tween Dielmo and Ndiop by age group for the two periods
were also compared (Figure 4). The differences between
Dielmo and Ndiop were statistically significant for 2000:
all nominal p values were less than 0.001. However for
2010, the mean OD ratios of IgG antibodies did not differ
significantly between Dielmo and Ndiop.
The 5–9 years of age group in 2000 was compared
with the corresponding the 15–19 years of age group in
2010. The mean IgG antibody OD ratios were signifi-
cantly higher in the [5-9] group in 2000 than in the
corresponding [15-19] group in 2010 in both villages
(Figures 3 and 4). This finding contrasts with the finding
that the prevalence in Ndiop did not differ between these
groups (Figure 2).
Discussion
The objectives of this study were to investigate the
prevalence of anti-malarial antibodies and the levels of
antibodies to crude extract of schizonts of a local P. fal-
ciparum strain. The ideal test for detecting malarialFigure 3 Antibody responses to crude extracts Sch07/03 according to
Ndiop in 2000 and 2010 in positive responders only.antibodies in epidemiological studies would be specific,
give reproducible results and could be used at large
scale. Therefore, the ELISA method was used as a tech-
nique suitable for high throughput and reproducible
testing. Another advantage of this technique is its low
cost, facilitating generalized and standardized use in the
areas where it is needed.
Many seroepidemiological analyses have used a single
recombinant antigen to evaluate serological responses.
This strategy does not favour sensitivity and may lead to
substantial underestimation of the immune response to P.
falciparum infection. Antigenic polymorphism and the di-
versity of individual responsiveness can have large effects
on the serological responses observed, and thus on the re-
sults obtained with recombinant antigens [18,19]. By con-
trast, crude extracts containing numerous antigens may
allow greater sensitivity and thus detection of low-level re-
sidual transmission. ELISA based on crude extracts is,
therefore, more informative and a better tool for following
endemicity [5,20].
In this study a schizonts crude extract of PfSch07/03 was
used in the ELISA as a tool to measure and compare im-
mune responses and seroprevalence. Antibody responses
against this crude extract of PfSch07/03 of subjects re-
cruited in the villages of Dielmo and Ndiop for antibodies
were analysed.
This study was conducted in the villages of Dielmo
and Ndiop. These villages were selected because the
epidemiological contexts were different. Dielmo was
holoendemic with a perennial and high transmission,
with 200 to 300 infected bites/person/year [13] whereas
Ndiop was a mesoendemic area with moderate andage group: comparison of the responses between Dielmo and
Figure 4 Antibody responses to crude extracts Sch07/03 according to age group: comparison of the responses between Dielmo and
Ndiop in 2000 and 2010 in all subjects.
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September and December), with 20 to 30 infected bites/
person/year (10 fold less than in Dielmo). However, by
2010, the EIR had decreased to 79 infected bites/per-
son/year in Dielmo and to 4.6 infected bites/person/year
in Ndiop.
Seropositivity to PfSch07/03 crude extracts was tested
among the inhabitants of Dielmo and Ndiop for the years
2000 (220 subjects) and 2010 (222 subjects). The preva-
lence of anti-P. falciparum Abs differed between Dielmo
and Ndiop in 2000. The seroprevalence to PfSch07/03 was
high for all age groups studied in Dielmo, and highest in
young adults (around 100%) in 2000. This high seropreva-
lence to PfSch07/03 is consistent with the high levels of
exposure in this region of perennial transmission and
holoendemicity [21]. The seroprevalence in Ndiop in-
creased with age in 2000 and was at 83.6% for 15–19 yrs
older group. This reflects the seasonal transmission and
the delay in acquiring an immune response as described
by Perraut et al. [22]. These findings are in agreement
with seminal epidemiological reports [23-25]. Studies
conducted before the introduction of intensive malaria
control programmes reported a higher prevalence and
protective role of antibodies in the endemic Dielmo and
Ndiop areas [21] and West African countries more gener-
ally [26]. The seroprevalence had declined substantially
after 10 years in both Dielmo (44.4%) and Ndiop (34.6%),
such that they were similar in the two villages in 2010; this
is presumably a consequence of the anti-malarial strat-
egies implemented since 2008 in Senegal [27]. There was
no significant difference in seroprevalence between males
and females in Dielmo or Ndiop, in either year (p > 0.05).These findings are in agreement with previous epidemio-
logical studies [28].
Differences in the increases and decreases of antibody
prevalence between age groups were also considered.
Seroprevalence decreased further and more significantly
in the youngest group (by more than 40%) than the
oldest group (less than 19%). There is probably a delay
before acquiring an immune response in younger indi-
viduals, whereas adults display a ‘memory effect’ and
their immune response can persist as a consequence of a
history of contact with the parasite [29,30]. This could
be due to the change of endemicity in Dielmo where
transmission has declined following implementation of
control programmes [27,31]. Similar findings have also
been reported in other western African countries in
2013 [32]. The analyses of the anti- PfSch07/03 IgG
response in the youngest age group in 2000 (correspond-
ing to the 15–19 year-old group in 2010) revealed
another interesting feature of malaria transmission and
seroprevalence: the percentage of positive subjects in
Dielmo was significantly lower 10 years later, suggesting
that adults had, by 2010 lost the immune response to
malaria antigens that they had had when they were ten
years younger. By contrast, in Ndiop the seroprevalence
was unchanged after 10 years in the same group. This
observation might reflect the low intensity of transmis-
sion, especially among adults, in Ndiop.
The mean levels of anti- PfSch07/03 Abs decreased
substantially between 2000 and 2010 in both Dielmo
and Ndiop. These declines were such that the magnitude
of antibody responses did not differ between the two vil-
lages in 2010. Although seroprevalence appears to have
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levels of Abs responses were highly significantly different
between the younger group in 2000 and the correspond-
ing older group in 2010. The decrease of the antibodies
levels was comparable in Dielmo and Ndiop suggesting
that a similar mechanism was operating to reduce mal-
aria prevalence in the two villages. Trape et al. reported
a longitudinal follow up of inhabitants of Dielmo, showing
that the incidence density decreased after LLITN distribu-
tion [31]. Recent reports in Gambia demonstrate that
these policies substantially reduce malaria morbidity, mor-
tality and prevalence [26]. The present study argues that
sero-epidemiology could be a valuable additional monitor-
ing tool particularly in the context of pre-elimination of
malaria. The standardization by different laboratories of
this method based on using crude extracts of P. falcip-
arum in assessments of the overall anti-blood-stage im-
mune responses would make this approach even more
useful for monitoring exposure to malaria.
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